

BRAWN BIOTECH LIMITED
(Formerly Known as Brawn Pharmaceuticals Limited)
Regd Office: C-64, Lajpat Nagar-1, New Delhi 110024

Statement of Standalone Audited Financial Results for the quarter & year ended 31st March, 2015

PART I						(Rs. in Lakhs)	(Rs. in Lakhs)
	Particulars	3 months ended 31/03/2015	Preceding 3 months ended 31/12/2014	Corresponding 3 months ended 31/03/2014 in the previous year	Year to date figures for current period ended 31/03/2015	Previous Year ended 31/03/2014	Previous year ended 31/03/2012
		Unaudited	Unaudited	Unaudited	Audited	Audited	Audited
1	Income from operations						
	Net sales/ income from operations (Net of excise duty)	776.51	1,147.67	945.09	3,798.08	3,670.43	1,454.77
	Other operating Income	18.30	18.53	30.01	66.56	106.81	51.62
	Total income from operations (net)	794.81	1,166.20	975.10	3,864.64	3,777.24	1,506.39
2	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	686.78	1,048.47	579.93	3,332.58	2,830.54	713.53
	(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	1.15	(6.94)	(32.00)	68.31	(11.23)	(38.08)
	(d) Employee benefits expense	44.42	38.69	59.76	151.82	283.35	411.12
	(e) Depreciation and amortisation expenses	0.25	0.81	0.47	2.62	1.47	0.91
	(f) Other expenses	39.30	70.16	347.62	256.20	629.77	393.75
	Total expenses	771.91	1,151.19	955.78	3,811.54	3,733.90	1,481.23
3	Profit / (Loss) from operation before other income, finance costs and exceptional items (1-2)	22.91	15.01	19.33	53.11	43.34	25.16
4	Other income	3.60	-	2.45	5.18	71.24	0.06
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3±4)	26.50	15.01	21.78	58.28	114.58	25.22
6	Finance Cost	9.63	0.21	11.12	10.45	14.20	5.05
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5±6)	16.88	14.80	10.66	47.84	100.38	1,756.92
8	Exceptional items	-	-	36.23	-	77.63	-
9	Profit / (Loss) from ordinary activities before tax (7±8)	16.88	14.80	(25.57)	47.84	22.75	1,756.92
10	Tax expense	-	6.40	(4.39)	19.41	8.30	17.84
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	16.88	8.40	(21.18)	28.43	14.45	1,739.08
12	Extraordinary items (net of tax expense)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11±12)	16.88	8.40	(21.18)	28.43	14.45	1,739.08

	Particulars	3 months ended 31/03/2015	3 months ended 31/03/2013
B	INVESTOR COMPLAINTS		
	Pending at the beginning of the quarter	Nil	Nil
	Received during the quarter	Nil	Nil
	Disposed of during the quarter	Nil	Nil
	Remaining unresolved at the end of the quarter	Nil	Nil

BRAWN BIOTECH LIMITED
(Formerly Known as Brawn Pharmaceuticals Limited)
Regd Office: C-64, Lajpat Nagar-1, New Delhi 110024

Standalone Audited Statement of Assets & Liabilities

(Rs. in Lakhs)

	Particulars	As at 31/03/2015	As at 31/03/2014
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	300.03	300.03
	(b) Reserves and Surplus	193.71	167.95
	Sub-Total - Shareholders' funds	493.74	467.98
2	Non-current liabilities		
	(a) Long Term Borrowings	-	-
	(b) Deferred Tax Liabilities (net)	0.26	-
	(c) Long Term Provisions	7.18	6.83
	Sub-Total - Non-current liabilities	7.44	6.83
3	Current liabilities		
	(a) Short Term Borrowings	10.99	0.61
	(b) Trade Payables	679.88	677.74
	(c) Other Current Liabilities	131.30	159.67
	(d) Short Term Provisions	76.97	56.88
	Sub-Total - Current liabilities	899.13	894.91
	TOTAL - EQUITY AND LIABILITIES ASSETS	1,400.32	1,369.71
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	18.92	7.29
	(b) Non-Current Investments	3.00	3.00
	(c) Deferred Tax Assets (net)	-	1.12
	(d) Long Term Loans and Advances	18.27	30.09
	(e) Other non Current Assets	268.16	268.16
	Sub-Total - Non-current assets	308.35	309.67
2	Current assets		
	(a) Inventories	102.78	171.09
	(b) Trade Receivables	921.51	836.46
	(c) Cash and Cash Equivalents	24.98	18.83
	(d) Short Term Loans and Advances	42.70	33.68
	(e) Other Current Assets	-	-
	Sub-Total - Current	1,091.97	1,060.05
	TOTAL	1,400.32	1,369.71

Notes:

- The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its Meeting held on 29.05.2015 and have been audited by the Statutory Auditors of the Company. The figures of the last quarter are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current Financial Year.
- Figures of the previous periods have been regrouped and/or rearranged wherever necessary, to confirm to the current period's classification.
- Pursuant to the requirement of the Schedule II of the Companies Act, 2013, the Company has revised the depreciation rates w.e.f. 01.04.2014, as prescribed under the said act. Therefore the Company has adjusted the net residual value aggregating to Rs.2.67 Lac from retained earning and the depreciation for March 2015 quarter and year 2014-15 is higher by Rs.0.61 Lac.

**For and on behalf of Board
For Brawn Biotech Limited**

Place: New Delhi
Date: 29.05.2015

Trilok Singh
Director
DIN- 06770266